EFTUD2 and hepatocellular carcinoma: EFTUD2 has been noted to increase hepatocellular carcinoma (HCC) cell survival and metastasis by inducing epithelial–mesenchymal transition and be associated with immune infiltration and poor prognosis, making it a potential therapeutic target for liver cancer (20–22).